TPA and CA 15.3 concentrations were routinely determined in serum of patients treated for breast cancer during a 15-month period. ROC curves did not show differences in the ability to differentiate between NED and PD on the basis of matching tumor marker values. During monitoring of patients with NED, TPA levels showed fluctuations of more than 25% that were not disease related. We concluded that CA 15.3 is a more slowly reacting marker of tumor burden than TPA, which is an immediate indicator of cell turnover.
HayesD.F., ZurawskiV.R., KufeD.W.Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer.J Clin Oncol1986; 4: 1542–50.
2.
GionM., MioneR., DittadiR., FasanS., PalliniA., BruscagninG.Evaluation of CA 15.3 serum levels in breast cancer patients.J Nucl Med Allied Sci1986; 30: 29–36.
3.
Van DalenA.Tumour markers in breast cancer.Ann Chirurgiae Gynaecol1989; 78: 54–64.
4.
BottiniA., BerrutiA., TampelliniM.Influence of neoadjuvant chemotherapy on serum tumor markers CA 15.3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.Tumor Biol1997; 18: 301–10.
5.
NemotoT., CostantineR., ChuT.M.Human tissue polypeptide antigen in breast cancer.J Natl Cancer Inst1979; 63: 1347–50.
6.
HirschbergL., BonfrerJ.M.G., AronssonA-C, PisaE.K.Liaison TPA, an automated chemiluminescence immunoassay for the determination of the predominant cytokeratins 8, 18 and 19.Tumor Biol1998; 19(S2): 53.
7.
BonfrerJ.M.G.The use of CA 15.3 in breast cancer. In TorreC.G., ed. I marker tumorali in ginecologia.S. Terenzo di Lerici, CiC. Edizione Internazionale1985; 63.
8.
KjellgrenK.The prognostic significance of consecutive determinations of serum tissue polypeptide antigen (S-TPA) in human breast cancer. In: LehmanF-G, ed. Carcino-embryonic proteins, Vol. II.Amsterdam: Elsevier, 1979; 607–10.
9.
Schmidt-RhodeP., SchulzK-D, WinterS., WürzH., SturmG.Tissue polypeptide antigen in patients with breast cancer and gynecological cancer.Prot Biol Fl1984; 31: 449–52.
10.
SafiF., KohlerI., RottingerE.Comparison of CA 15.3 and CEA in diagnosis and monitoring of breast cancer.Int J Biol Markers1989; 4: 207–14.
11.
VizcarraE., LluchA., CibriánR.Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.Breast Cancer Res Treatment1996; 37: 209–16.
12.
BlijlevensN.M.A., OosterhuisW.P., OostenH.R., MulderN.H.Clinical value of TPS, CEA and CA15.3 in breast cancer patients.Anticancer Res1995; 15: 2711–6.
13.
NicoliniA., ColombiniC., LucianiL., CarpiA., GiulianiL.Evaluation of serum CA 15.3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.Br J Cancer1991; 64: 154–8.
14.
Van DalenA.TPS in breast cancer-A comparative study with carcinoembryonic antigen and CA 15.3.Tumor Biol1992; 13: 10–7.
